

Prevalence and Treatment of Psoriasis in the United Kingdom

Archives of Dermatology

141, 1537-41

DOI: [10.1001/archderm.141.12.1537](https://doi.org/10.1001/archderm.141.12.1537)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advances in Psoriasis. Archives of Dermatology, 2005, 141, 1589-90.	1.7	5
3	Prevalence of cardiovascular risk factors in patients with psoriasis. Journal of the American Academy of Dermatology, 2006, 55, 829-835.	0.6	889
4	Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. British Journal of Dermatology, 2006, 155, 1236-1241.	1.4	33
5	The Risk of Lymphoma in Patients with Psoriasis. Journal of Investigative Dermatology, 2006, 126, 2194-2201.	0.3	265
6	Risk of Myocardial Infarction in Patients With Psoriasis. JAMA - Journal of the American Medical Association, 2006, 296, 1735.	3.8	1,571
7	The epidemiology of psoriasis. Expert Review of Dermatology, 2006, 1, 63-75.	0.3	87
8	Calcipotriene/betamethasone dipropionate: a new topical ointment for psoriasis. Expert Review of Dermatology, 2006, 1, 791-797.	0.3	1
9	Identification of Susceptibility Loci for Skin Disease in a Murine Psoriasis Model. Journal of Immunology, 2006, 177, 4612-4619.	0.4	7
10	Management of psoriasis in pregnancy. BMJ: British Medical Journal, 2007, 334, 1218-1220.	2.4	61
11	Immune-mediated inflammatory diseases (IMiDs) and biologic therapy: a medical revolution. Postgraduate Medical Journal, 2007, 83, 251-260.	0.9	257
12	Clinical Severity of Psoriasis in Last 20 Years of PUVA Study. Archives of Dermatology, 2007, 143, 1113-21.	1.7	30
13	Update on the epidemiology and systemic treatment of psoriasis. Expert Review of Clinical Immunology, 2007, 3, 171-185.	1.3	22
14	The Risk of Mortality in Patients With Psoriasis. Archives of Dermatology, 2007, 143, 1493-9.	1.7	439
15	Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women. Archives of Internal Medicine, 2007, 167, 1670.	4.3	396
16	Incidence and Risk Factors for Psoriasis in the General Population. Archives of Dermatology, 2007, 143, 1559-65.	1.7	279
17	La psoriasis, ¿una enfermedad sistémica?. Actas Dermo-sifiligráficas, 2007, 98, 396-402.	0.2	31
18	Smoking and the Risk of Psoriasis in Women: Nurses' Health Study II. American Journal of Medicine, 2007, 120, 953-959.	0.6	157
19	Epidemiology of autoimmune diseases in Denmark. Journal of Autoimmunity, 2007, 29, 1-9.	3.0	351

#	ARTICLE	IF	CITATIONS
20	Efficacy and Safety of Etanercept in Psoriasis/Psoriatic Arthritis. American Journal of Clinical Dermatology, 2007, 8, 143-155.	3.3	53
21	Psoriasis, a Systemic Disease?. Actas Dermo-sifilograficas, 2007, 98, 396-402.	0.2	10
22	Post-treatment skin reactions reported by cancer patients differ by race, not by treatment or expectations. British Journal of Cancer, 2007, 97, 14-21.	2.9	38
23	Srcasm overexpression in psoriasis-insights into pathogenesis. Journal of Cutaneous Pathology, 2007, 34, 160-165.	0.7	5
24	A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis. Seminars in Arthritis and Rheumatism, 2007, 37, 164-173.	1.6	37
26	Regional distribution of psoriasis in Italy. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 324-329.	1.3	46
27	Lifetime prevalence fluctuations of chronic plaque psoriasis and other nonâ€pustular clinical variants. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1513-1514.	1.3	5
28	Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1062-1069.	1.3	55
29	Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based caseâ€control study. British Journal of Dermatology, 2008, 158, 1299-1307.	1.4	68
30	Long-term prognosis in patients with psoriasis. British Journal of Dermatology, 2008, 159, 2-9.	1.4	101
31	Psoriasis and the risk of incident diabetes mellitus: a population-based study. British Journal of Dermatology, 2008, 159, 1331-1337.	1.4	95
32	Psoriasis: The heart of the matter. Journal of the American Academy of Dermatology, 2008, 58, 477-478.	0.6	2
33	Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. Journal of the American Academy of Dermatology, 2008, 58, 421-429.	0.6	62
34	Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. Journal of the American Academy of Dermatology, 2008, 58, 625-631.	0.6	141
35	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2008, 58, 826-850.	0.6	1,128
36	Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. Journal of the American Academy of Dermatology, 2008, 59, 295-315.	0.6	78
38	Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001â€2002. Dermatology, 2008, 217, 27-37.	0.9	155
39	Skin Diseases in Family Medicine: Prevalence and Health Care Use. Annals of Family Medicine, 2008, 6, 349-354.	0.9	67

#	ARTICLE	IF	CITATIONS
40	A mobile-phone based teledermatology system to support self-management of patients suffering from psoriasis. , 2008, 2008, 5338-41.		23
41	Cardiometabolic risk in psoriasis: differential effects of biologic agents. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1229-1235.	1.0	17
42	Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 141-148.	0.9	28
43	Treatment of severe psoriasis with infliximab. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1165-1175.	0.9	16
44	Is folic acid good for everyone?. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 517-533.	2.2	502
45	A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 294-302.	0.6	22
46	The Burden of Psoriasis in Canada: Insights from the p<u>S</u>oriasis <u>K</u>nowledge <u>IN</u> Canada (SKIN) Survey. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 235-252.	0.6	23
47	Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. <i>Dermatology</i> , 2009, 218, 103-109.	0.9	76
48	Management of cardiovascular disease risk in chronic inflammatory disorders. <i>Nature Reviews Rheumatology</i> , 2009, 5, 208-217.	3.5	57
49	Excessive Body Weight and Smoking Associates with a High Risk of Onset of Plaque Psoriasis. <i>Acta Dermato-Venereologica</i> , 2009, 89, 492-497.	0.6	127
50	Epidemiological Study of Psoriasis in the National Health Insurance Database in Taiwan. <i>Acta Dermato-Venereologica</i> , 2009, 89, 262-266.	0.6	110
51	Psoriasis Comorbidities. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S77-S87.	0.6	35
52	Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. <i>Rheumatology</i> , 2009, 48, 761-764.	0.9	92
53	Epidemiology and prescribed treatments in childhood psoriasis: A survey among medical professionals. <i>Journal of Dermatological Treatment</i> , 2009, 20, 254-258.	1.1	25
54	Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: Results of a 10 years follow-up study of 507 patients (ECHODIAH study). <i>Joint Bone Spine</i> , 2009, 76, 389-393.	0.8	6
55	Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. <i>British Journal of Dermatology</i> , 2009, 160, 1048-1056.	1.4	162
56	Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2009, 161, 159-166.	1.4	57
57	Development and pilot-testing of a psoriasis screening tool. <i>British Journal of Dermatology</i> , 2009, 161, 778-784.	1.4	44

#	ARTICLE	IF	CITATIONS
58	More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. <i>British Journal of Dermatology</i> , 2009, 161, 1-7.	1.4	116
59	The Risk of Stroke in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2411-2418.	0.3	358
60	Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Caseâ€“Control Analysis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2604-2612.	0.3	105
61	Lipid profile in patients with psoriasis in Zahedan, southâ€“east Iran. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 461-462.	1.3	2
62	308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 36-41.	1.3	43
63	PrÃ©valence et Ã©valuation de lâ€™impact du psoriasis sur lâ€™Ã©volution naturelle de la coxarthrose. RÃ©sultats dâ€™un suivi sur dix ans de 507 patients (Ã©tude Echodiah). <i>Revue Du Rhumatisme (Edition) Tj ETQ</i> 14 rgB	0.784314	14
64	The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 218-224.	0.6	417
65	Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 402-411.	0.6	40
66	The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 405-410.	0.6	99
67	Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. <i>Journal of Autoimmunity</i> , 2009, 33, 197-207.	3.0	587
68	Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent. , 2009, , 229-254.		4
69	Calcipotriene plus betamethasone dipropionate gel: a new combination therapy for scalp psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 111-118.	0.3	1
70	Economic burden of psoriasis compared to the general population and stratified by disease severity. <i>Current Medical Research and Opinion</i> , 2009, 25, 2429-2438.	0.9	86
71	The psychological sequelae of psoriasis: Results of a qualitative study. <i>Psychology, Health and Medicine</i> , 2009, 14, 150-161.	1.3	61
72	Lithium, Antipsychotics, and Risk of Psoriasis. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 134-140.	0.7	25
73	Psoriasis and cardiovascular diseases. <i>Acta Cardiologica</i> , 2010, 65, 337-340.	0.3	13
74	Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 835-842.	1.4	33
75	Treatment of scalp psoriasis with clobetasolâ€“17 propionate 0.05% shampoo: a study on daily clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 439-444.	1.3	13

#	ARTICLE	IF	CITATIONS
76	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 548-554.	1.3	135
77	The relation between different dimensions of alcohol consumption and burden of disease: an overview. <i>Addiction</i> , 2010, 105, 817-843.	1.7	871
78	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , 2010, 162, 137-146.	1.4	82
79	Epidemiology and comorbidity of psoriasis in children. <i>British Journal of Dermatology</i> , 2010, 162, 633-636.	1.4	375
80	A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2010, 163, 807-816.	1.4	54
81	A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. <i>British Journal of Dermatology</i> , 2010, 163, 1099-1101.	1.4	72
82	PsorÃase e obesidade: revisÃ£o de literatura e recomendaÃ§Ãµes no manejo. <i>Anais Brasileiros De Dermatologia</i> , 2010, 85, 355-360.	0.5	37
83	Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. <i>Rheumatology</i> , 2010, 49, 1949-1956.	0.9	40
84	The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 891-5.	1.7	530
85	Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: An immunohistochemical study. <i>Journal of Dermatological Treatment</i> , 2010, 21, 13-22.	1.1	20
86	Psoriasis and Multiple Sclerosis: Is There a Link?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010, 14, 151-155.	0.6	22
87	Psoriasis Affects Individuals of African Descent and White Brazilians Similarly. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2010, 101, 230-234.	0.2	0
88	Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. <i>European Heart Journal</i> , 2010, 31, 1000-1006.	1.0	577
89	Incidence of psoriasis in children: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 979-987.	0.6	214
90	Geoeidemiology and environmental factors of psoriasis and psoriatic arthritis. <i>Journal of Autoimmunity</i> , 2010, 34, J314-J321.	3.0	403
91	Psoriasis affects individuals of African descent and white Brazilians similarly. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2010, 101, 230-234.	0.2	7
92	Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. <i>Current Medical Research and Opinion</i> , 2011, 27, 269-284.	0.9	18
93	A psoriasis-specific model to support decision making in practice â€“ UK experience. <i>Current Medical Research and Opinion</i> , 2011, 27, 205-223.	0.9	14

#	ARTICLE	IF	CITATIONS
94	The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis – an introduction. <i>Current Medical Research and Opinion</i> , 2011, 27, 197-203.	0.9	2
95	Psoriasis and Obesity: A Review and Practical Recommendations. <i>Actas Dermo-sifiligráficas</i> , 2011, 102, 505-509.	0.2	2
96	IL-23/TH17 Pathway in Psoriasis and Inflammatory Skin Diseases. , 2011, , 463-480.		1
98	Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events. <i>American Journal of Medicine</i> , 2011, 124, 775.e1-775.e6.	0.6	267
99	Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 495-501.	0.6	73
100	Statin use and risk of first-time psoriasis diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 77-83.	0.6	34
101	Low prevalence of psoriasis among children and adolescents in a large multiethnic cohort in southern California. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 957-964.	0.6	43
102	The prevalence of psoriasis among elderly individuals: more questions than answers. <i>Ageing Research</i> , 2011, 2, 1.	0.8	2
103	Ustekinumab: differential use in psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2011, 4, 93.	0.8	4
104	JUVENILE PSORIATIC ARTHRITIS. , 2011, , 287-297.		3
105	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. <i>Psoriasis Forum</i> , 2011, 17a, 119-130.	0.1	0
106	Investigação de infecção tuberculosa latente em pacientes com psoríase candidatos ao uso de drogas imunobiológicas. <i>Anais Brasileiros De Dermatologia</i> , 2011, 86, 716-724.	0.5	6
107	Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. <i>British Journal of Dermatology</i> , 2011, 164, 103-109.	1.4	53
108	Validity of The Health Improvement Network (THIN) for the study of psoriasis. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	91
109	Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. <i>British Journal of Dermatology</i> , 2011, 165, 865-873.	1.4	166
110	The Association of Psoriasis and Elevated Blood Lipids in Overweight and Obese Children. <i>Journal of Pediatrics</i> , 2011, 159, 577-583.	0.9	98
112	Management of psoriasis and its comorbidities in primary care. <i>British Journal of Nursing</i> , 2011, 20, 1186-1192.	0.3	6
113	Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography – Computed Tomography (FDG-PET/CT). <i>Archives of Dermatology</i> , 2011, 147, 1031.	1.7	194

#	ARTICLE	IF	CITATIONS
114	Canadian Guidelines for the Management of Plaque Psoriasis: Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 210-219.	0.6	76
115	Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish health professionals. <i>Current Medical Research and Opinion</i> , 2011, 27, 239-249.	0.9	7
116	Prevalence of the Metabolic Syndrome in Psoriasis. <i>Archives of Dermatology</i> , 2011, 147, 419.	1.7	236
117	Management of Psoriasis in Africa and the Middle East: A Review of Current Opinion, Practice and Opportunities for Improvement. <i>Journal of International Medical Research</i> , 2011, 39, 1573-1588.	0.4	14
118	Teledermatological Monitoring of Psoriasis Patients on Biologic Therapy. <i>Acta Dermato-Venereologica</i> , 2011, 91, 680-685.	0.6	46
119	Psychological Stress and the Cutaneous Immune Response: Roles of the HPA Axis and the Sympathetic Nervous System in Atopic Dermatitis and Psoriasis. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-11.	0.3	119
120	Trends in Pediatric Psoriasis Outpatient Health Care Delivery in the United States. <i>Archives of Dermatology</i> , 2012, 148, 66.	1.7	30
121	Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1361-1365.	0.5	37
122	Celiac Disease and Dermatologic Manifestations: Many Skin Clue to Unfold Gluten-Sensitive Enteropathy. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-12.	0.7	38
123	Gender-related differences in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 641-649.	0.3	15
124	Acitretin exerted a greater influence on Th1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris. <i>Journal of Dermatology</i> , 2012, 39, 916-921.	0.6	36
125	Space-based estimation of the solar UV-B doses for psoriasis heliotherapy in Poland using OMI data for the period 2005–2011. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2012, 117, 240-246.	1.7	12
126	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 553-556.	0.5	136
127	Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. <i>British Journal of Dermatology</i> , 2012, 167, 1345-1350.	1.4	80
128	Psoriasis: rationale for targeting interleukin-17. <i>British Journal of Dermatology</i> , 2012, 167, 717-724.	1.4	120
129	Increased Risk of Diabetes Mellitus and Likelihood of Receiving Diabetes Mellitus Treatment in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 995-1000.	1.7	113
130	Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 357-362.	0.6	57
131	The association of psoriasis with autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 924-930.	0.6	176

#	ARTICLE	IF	CITATIONS
132	Nail Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 375-388.	3.3	83
133	The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2012, 13, 236.	0.7	4
135	Prescribing for mild-to-moderate psoriasis in adults. <i>NursePrescribing</i> , 2012, 10, 582-589.	0.1	3
136	Exercise for a healthy brain. <i>Nursing and Residential Care</i> , 2012, 14, 625-625.	0.1	0
137	Childhood Plaque Psoriasis: Case Report of Successful Treatment with Ustekinumab and Review of Systemic Therapies. <i>Psoriasis Forum</i> , 2012, 18a, 75-80.	0.1	0
138	Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: A nationwide cohort study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1879-1887.	6.7	40
139	A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis. <i>Current Dermatology Reports</i> , 2012, 1, 14-22.	1.1	0
140	Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 222-229.	0.7	22
141	The prevalences of some rheumatic diseases in western Turkey: Havsa study. <i>Rheumatology International</i> , 2012, 32, 895-908.	1.5	80
142	Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 59-65.	1.3	41
143	Bacterial skin flora and contamination of blood components: do we defer blood donors wisely?. <i>Vox Sanguinis</i> , 2012, 103, 93-98.	0.7	8
144	Psoriasis increased the risk of diabetes: a meta-analysis. <i>Archives of Dermatological Research</i> , 2012, 304, 119-125.	1.1	39
145	Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. <i>Journal of Dermatological Treatment</i> , 2013, 24, 193-198.	1.1	38
146	Body weight increment in patients treated with infliximab for plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e186-90.	1.3	46
147	Increased Risk of Sexual Dysfunction in Male Patients with Psoriasis: A Nationwide Population-Based Follow-Up Study. <i>Journal of Sexual Medicine</i> , 2013, 10, 1212-1218.	0.3	30
148	Psoriasis and Psycho-Dermatology. <i>Dermatology and Therapy</i> , 2013, 3, 117-130.	1.4	41
149	Outcome Measures in Psoriatic Disease. <i>Current Dermatology Reports</i> , 2013, 2, 164-171.	1.1	0
150	Risk Factors for Psoriasis. <i>Current Dermatology Reports</i> , 2013, 2, 58-65.	1.1	12

#	ARTICLE	IF	CITATIONS
151	Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. <i>British Journal of Dermatology</i> , 2013, 169, 889-895.	1.4	45
153	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 842-849.	0.9	94
154	Psoriasis Severity and the Prevalence of Major Medical Comorbidity. <i>JAMA Dermatology</i> , 2013, 149, 1173.	2.0	402
155	Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. <i>BMC Dermatology</i> , 2013, 13, 9.	2.1	23
156	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013, 305, 891-897.	1.1	15
157	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013, 15, R136.	1.6	212
158	Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. <i>British Journal of Dermatology</i> , 2013, 168, 1303-1310.	1.4	188
159	Role of psoriasis as independent predictor of cardiovascular disease: A meta-regression analysis. <i>International Journal of Cardiology</i> , 2013, 168, 2282-2288.	0.8	38
160	Hair-zinc levels determination in Algerian psoriatics using Instrumental Neutron Activation Analysis (INAA). <i>Applied Radiation and Isotopes</i> , 2013, 72, 177-181.	0.7	12
161	Recognition of need in health care consultations: a qualitative study of people with psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 354-361.	1.4	69
162	Pregnancy and dermatologic therapy. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 663-671.	0.6	41
163	Clinical and Histologic Diagnostic Guidelines for Psoriasis: A Critical Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 166-172.	2.9	58
164	Association of Pediatric Psoriasis Severity With Excess and Central Adiposity. <i>JAMA Dermatology</i> , 2013, 149, 166.	2.0	148
165	Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 654-662.	0.6	327
166	Psoriasis and the Risk of Diabetes Mellitus. <i>JAMA Dermatology</i> , 2013, 149, 84.	2.0	262
167	Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4521-4536.	2.9	72
168	Biological treatments for moderate-to-severe psoriasis: indirect comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 121-130.	0.7	37
169	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. <i>Journal of Investigative Dermatology</i> , 2013, 133, 377-385.	0.3	1,827

#	ARTICLE	IF	CITATIONS
170	TDP-43 frontotemporal lobar degeneration and autoimmune disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 956-962.	0.9	137
171	Psoriasis and phenotype of patients with early inflammatory back pain. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 566-571.	0.5	27
172	Effect of Weight Loss on the Severity of Psoriasis. <i>JAMA Dermatology</i> , 2013, 149, 795.	2.0	175
173	Comorbidities of psoriasis. <i>Expert Review of Dermatology</i> , 2013, 8, 277-290.	0.3	2
174	There Is Hope: Autogenic Biofeedback Training for the Treatment of Psoriasis. <i>Biofeedback</i> , 2013, 41, 194-201.	0.3	3
175	Assessment of Female Sexual Function in Patients with Psoriasis. <i>Journal of Sexual Medicine</i> , 2013, 10, 1545-1548.	0.3	33
176	An overview of psoriasis and the role of emollient therapy. <i>British Journal of Community Nursing</i> , 2013, 18, 174-179.	0.2	13
177	Standardizing Training for Psoriasis Measures. <i>JAMA Dermatology</i> , 2013, 149, 577.	2.0	42
178	Immunotargeting in the management of psoriasis. <i>ImmunoTargets and Therapy</i> , 2013, 2, 51.	2.7	2
179	Older people and psoriasis: the use of emollient therapy. <i>Nursing and Residential Care</i> , 2013, 15, 476-480.	0.1	1
180	Psoriasis: exploring the associated clinical issues and how to support your patients. <i>Journal of Aesthetic Nursing</i> , 2013, 2, 111-117.	0.0	0
181	Managing psoriasis in children and young people. <i>NursePrescribing</i> , 2013, 11, 330-336.	0.1	1
182	Dietary Status in Albanian Patients with Rheumatoid Arthritis. <i>Academic Journal of Interdisciplinary Studies</i> , 2014, , .	0.3	0
183	Validity of Diagnostic Codes and Prevalence of Physician-Diagnosed Psoriasis and Psoriatic Arthritis in Southern Sweden – A Population-Based Register Study. <i>PLoS ONE</i> , 2014, 9, e98024.	1.1	94
184	Epidemiology and treatment of psoriasis: a Chinese perspective. <i>Psoriasis: Targets and Therapy</i> , 0, , 37.	1.2	4
185	Vitamin D and Psoriasis Pathology in the Mediterranean Region, Valencia (Spain). <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 12108-12117.	1.2	11
186	Interleucina-17 como Alvo Terapêutica na Psoríase. <i>Acta Medica Portuguesa</i> , 2014, 27, 252-258.	0.2	7
187	A Review of Tofacitinib in the Treatment of Rheumatoid Arthritis and Psoriasis. <i>Psoriasis Forum</i> , 2014, 20a, 108-120.	0.1	0

#	ARTICLE	IF	CITATIONS
188	Evaluating the Effectiveness of Psychological Interventions in Patients with Psoriasis: A Review. Psoriasis Forum, 2014, 20a, 8-15.	0.1	3
189	Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. Journal of Dermatological Treatment, 2014, 25, 67-72.	1.1	13
190	Childhood and adolescent psoriasis in Greece: a retrospective analysis of 842 patients. International Journal of Dermatology, 2014, 53, 1447-1453.	0.5	12
191	Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis. Dermatology Research and Practice, 2014, 2014, 1-6.	0.3	6
192	Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?. Expert Review of Clinical Immunology, 2014, 10, 763-770.	1.3	14
193	Psoriasis Uncovered – Comorbid Conditions with Special Reference to Metabolic Syndrome. Nasza Dermatologia Online, 2014, 5, 14-17.	0.0	2
194	Objective erythema assessment of Psoriasis lesions for Psoriasis Area and Severity Index (PASI) evaluation. , 2014, , .		7
195	Association between psoriasis and coronary calcium score. Atherosclerosis, 2014, 237, 847-852.	0.4	40
196	Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 327-332.	1.3	23
197	Childhood Psoriasis – An Analysis of German Health Insurance Data. Pediatric Dermatology, 2014, 31, 8-13.	0.5	37
198	Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. British Journal of Dermatology, 2014, 171, 602-608.	1.4	14
199	Psoriasis and smoking: a systematic review and meta-analysis. British Journal of Dermatology, 2014, 170, 304-314.	1.4	199
200	Evaluating the effectiveness of psychological and/or educational interventions in psoriasis: A narrative review. Journal of Dermatology, 2014, 41, 775-778.	0.6	18
201	Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1233-1236.	1.0	5
202	Current and potential immune therapies and vaccines in the management of psoriasis. Human Vaccines and Immunotherapeutics, 2014, 10, 876-886.	1.4	6
203	Pediatric Psoriasis. , 2014, , 253-276.		1
204	Serum concentrations of interleukin-2 and tumour necrosis factor- β under cyclosporine versus acitretin treatment in plaque-type psoriasis. Journal of International Medical Research, 2014, 42, 1118-1122.	0.4	11
205	Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. British Journal of Dermatology, 2014, 171, 1470-1477.	1.4	32

#	ARTICLE	IF	CITATIONS
206	In psoriasis, levels of hope and quality of life are linked. Archives of Dermatological Research, 2014, 306, 661-666.	1.1	35
207	Genetic Epidemiology of Psoriasis. Current Dermatology Reports, 2014, 3, 61-78.	1.1	74
208	Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease?. Drugs, 2014, 74, 169-182.	4.9	16
209	Non-bullous Skin Diseases. , 2014, , 971-989.		0
210	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Journal of the American Academy of Dermatology, 2014, 71, 141-150.	0.6	267
211	Psoriasis as a systemic disease. Clinics in Dermatology, 2014, 32, 343-350.	0.8	126
212	Increased prevalence of psoriasis in patients with coronary artery disease: results from a caseâ€control study. British Journal of Dermatology, 2014, 171, 580-587.	1.4	15
213	Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. British Journal of Dermatology, 2014, 170, 672-680.	1.4	74
214	Cardiovascular comorbidities in childhood psoriasis. European Journal of Dermatology, 2014, 24, 229-235.	0.3	30
215	Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years. European Journal of Dermatology, 2014, 24, 356-360.	0.3	4
217	Challenges and promises in modeling dermatologic disorders with bioengineered skin. Experimental Biology and Medicine, 2014, 239, 1215-1224.	1.1	16
218	Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 2014, 70, 512-516.	0.6	650
219	Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors. American Journal of Medicine, 2014, 127, 12-18.	0.6	68
220	Assessment of Atrial Electromechanical Delay and Pâ€Wave Dispersion in Patients with Psoriasis. Echocardiography, 2014, 31, 1071-1076.	0.3	15
221	Diagnosis and management of psoriatic arthropathy in primary care. British Journal of General Practice, 2014, 64, 424-425.	0.7	9
222	Realâ€life effectiveness of onceâ€daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52â€week <sc>PRO</sc>â€long study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2349-2355.	1.3	33
223	Effect of starchâ€fortified turmeric bath on psoriasis: a parallel randomised controlled trial. Focus on Alternative and Complementary Therapies, 2015, 20, 125-129.	0.1	4
224	Reduction of Inter-Rater and Intra-Rater Variability in Psoriasis Area and Severity Index Assessment by Photographic Training. Annals of Dermatology, 2015, 27, 557.	0.3	19

#	ARTICLE	IF	CITATIONS
225	Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis. The Cochrane Library, 0, , .	1.5	1
226	Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. BioMed Research International, 2015, 2015, 1-7.	0.9	93
227	Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology, 2015, 231, 35-40.	0.9	126
228	Working together to manage common skin conditions. British Journal of Nursing, 2015, 24, 1052-1053.	0.3	0
229	Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain. European Journal of Dermatology, 2015, 25, 410-417.	0.3	3
230	Proteomics of Skin Proteins in Psoriasis: From Discovery and Verification in a Mouse Model to Confirmation in Humans. Molecular and Cellular Proteomics, 2015, 14, 109-119.	2.5	38
231	Similarities in Coronary Function and Myocardial Deformation Between Psoriasis and Coronary Artery Disease: The Role of Oxidative Stress and Inflammation. Canadian Journal of Cardiology, 2015, 31, 287-295.	0.8	59
232	The global burden of psoriatic skin disease. British Journal of Dermatology, 2015, 172, 1665-1668.	1.4	64
233	Association between psoriasis, diabetes mellitus, hypertension and obesity. Clinical Epidemiology and Global Health, 2015, 3, 132-136.	0.9	1
234	Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open, 2015, 5, e006450-e006450.	0.8	222
235	Psoriasis and psoriatic arthritis in African-American patientsâ€”the need to measure disease burden. Clinical Rheumatology, 2015, 34, 1753-1759.	1.0	40
236	Darwinian Medicine and Psoriasis. Actas Dermo-sifiligrÃ¡ficas, 2015, 106, 189-194.	0.2	0
237	Comparison of levels of serum copper, zinc, albumin, globulin and alkaline phosphatase in psoriatic patients and controls: A hospital based casecontrol study. Indian Dermatology Online Journal, 2015, 6, 81.	0.2	21
238	Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatric Drugs, 2015, 17, 373-384.	1.3	160
239	EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb. Dermatology, 2015, 231, 134-144.	0.9	18
240	Psoriasis and risk of atrial fibrillation. International Journal of Cardiology, 2015, 185, 301-303.	0.8	5
241	Medicina darwiniana y psoriasis. Actas Dermo-sifiligrÃ¡ficas, 2015, 106, 189-194.	0.2	4
242	Association between psoriasis and asthma: a population-based retrospective cohort analysis. British Journal of Dermatology, 2015, 172, 1066-1071.	1.4	26

#	ARTICLE	IF	CITATIONS
243	Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. <i>International Journal of Obesity</i> , 2015, 39, 1197-1202.	1.6	87
244	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. <i>Current Opinion in Rheumatology</i> , 2015, 27, 91-98.	2.0	38
245	Atherosclerosis in psoriatic disease: latest evidence and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 187-195.	1.2	42
246	Assessment of Atrial Electromechanical Delay and Left Atrial Mechanical Functions in Patients with Psoriasis Vulgaris. <i>Echocardiography</i> , 2015, 32, 615-622.	0.3	11
247	Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 585-593.e3.	0.6	47
248	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 955-963.	1.3	81
249	Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. <i>British Journal of Dermatology</i> , 2015, 172, 419-427.	1.4	48
250	Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?. <i>Molecular and Cellular Biochemistry</i> , 2015, 400, 207-212.	1.4	31
251	Prevalence of Chronic Axial Pain, Inflammatory Back Pain, and Spondyloarthritis in Diagnosed Psoriasis. <i>Arthritis Care and Research</i> , 2015, 67, 829-835.	1.5	22
252	Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis. <i>Oral Diseases</i> , 2015, 21, 314-319.	1.5	39
253	Clinico-Biochemical Correlation Between Psoriasis and Insulin Resistance. <i>Indian Journal of Clinical Biochemistry</i> , 2015, 30, 99-103.	0.9	6
254	Prevalence and related factors of psoriasis and seborrheic dermatitis: a community-based study. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 303-309.	0.4	5
255	Is there any increased risk of hypertension, diabetes and cardiac diseases in psoriatic patients with TNF- α G238A and G308A polymorphism?. <i>Postepy Dermatologii i Alergologii</i> , 2016, 6, 440-444.	0.4	3
256	Evaluation of inhomogeneities of repolarization in patients with psoriasis vulgaris. <i>Archives of Medical Science</i> , 2016, 6, 1225-1231.	0.4	8
257	CCR6 ⁺ MCAM ⁺ Th17 Cell Numbers Increase in Patients with Psoriasis and Correlate with Disease Severity. <i>The Showa University Journal of Medical Sciences</i> , 2016, 28, 173-181.	0.1	0
258	Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. <i>Postepy Dermatologii i Alergologii</i> , 2016, 4, 247-252.	0.4	96
259	Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 743.	1.2	78
260	Epicardial fat tissue in patients with psoriasis: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2016, 15, 103.	1.2	29

#	ARTICLE	IF	CITATIONS
261	Psoriasis in children. Psoriasis: Targets and Therapy, 2016, Volume 6, 121-129.	1.2	19
262	Psoriasis and uric acid: a population-based cross-sectional study. Clinical and Experimental Dermatology, 2016, 41, 260-266.	0.6	19
263	The temporal association between cutaneous Tâ€œcell lymphoma and psoriasis: implications for common biologic processes. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e31-e32.	1.3	10
264	Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1742-1748.	1.3	14
265	Childhood psoriasis. European Journal of Dermatology, 2016, 26, 537-548.	0.3	46
266	Chapter 50 Low-Level Laser (Light) Therapy for Cosmetics and Dermatology. , 2016, , 1017-1048.		0
267	PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy. BMC Nephrology, 2016, 17, 185.	0.8	11
268	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology, 2016, 232, 655-663.	0.9	18
269	Peer-relationship-problems account for quality of life impairments in pediatric psoriasis. Journal of Psychosomatic Research, 2016, 84, 31-36.	1.2	6
270	Epigenome-Wide Association Analysis Identified Nine Skin DNA Methylation LociÂfor Psoriasis. Journal of Investigative Dermatology, 2016, 136, 779-787.	0.3	75
271	A randomized phase 2b trial of baricitinib, an oral Janus kinase (<sc>JAK</sc>) 1/JAK2 inhibitor, in patients with moderateâ€œtoâ€œsevere psoriasis. British Journal of Dermatology, 2016, 174, 1266-1276.	1.4	207
272	HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. Journal of Investigative Dermatology, 2016, 136, 2364-2371.	0.3	49
273	The epidemiology of childhood psoriasis: a scoping review. British Journal of Dermatology, 2016, 174, 1242-1257.	1.4	77
274	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and Therapy, 2016, 6, 151-167.	1.4	10
275	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 915-923.	2.9	197
276	Juvenile Psoriatic Arthritis. , 2016, , 256-267.e5.		4
277	Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study. Journal of Dermatological Treatment, 2016, 27, 399-405.	1.1	4
278	Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. Expert Review of Clinical Immunology, 2016, 12, 573-582.	1.3	11

#	ARTICLE	IF	CITATIONS
280	Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 69-76.e2.	0.6	27
281	Infliximab-induced skin manifestations in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 563-571.	0.6	38
282	Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 191.	2.0	34
283	Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 119-128.	1.4	18
284	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1680-1686.	0.5	85
285	Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <i>Journal of Dermatological Treatment</i> , 2017, 28, 129-135.	1.1	5
286	Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. <i>Arthritis Care and Research</i> , 2017, 69, 67-74.	1.5	153
287	Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 395-402.	1.4	22
288	An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 742-750.	1.4	13
289	Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>British Journal of Dermatology</i> , 2017, 177, 978-986.	1.4	41
290	Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study. <i>Journal of Dermatology</i> , 2017, 44, 621-629.	0.6	27
291	Myeloid but not plasmacytoid blood DCs possess Th1 polarizing and Th1/Th17 recruiting capacity in psoriasis. <i>Immunology Letters</i> , 2017, 189, 109-113.	1.1	11
292	Update on Comorbidities in Psoriasis. <i>Current Dermatology Reports</i> , 2017, 6, 129-136.	1.1	1
293	The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 293-301.e1.	0.6	11
294	Comparison of enhanced liver fibrosis test with procollagen-3-terminal peptide (P3NP) as a marker for liver fibrosis. <i>British Journal of Dermatology</i> , 2017, 176, 1439-1440.	1.4	0
295	A Clinical Review of Laser and Light Therapy for Nail Psoriasis and Onychomycosis. <i>Dermatologic Surgery</i> , 2017, 43, 161-172.	0.4	19
296	Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 583-590.	3.3	99
297	Investigation of 36 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in a psoriatic arthritis cohort. <i>Archives of Dermatological Research</i> , 2017, 309, 71-77.	1.1	10

#	ARTICLE	IF	CITATIONS
298	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-40S.	0.6	9
299	Dermatology prescribing update: Psoriasis. NursePrescribing, 2017, 15, 432-436.	0.1	0
300	Cardiometabolic Disorders in Psoriatic Disease. Current Rheumatology Reports, 2017, 19, 63.	2.1	25
301	Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor- α Antagonism or Cyclosporine in Psoriasis. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	63
302	Psychological effects of skin disease: the psoriasis exemplar. British Journal of Nursing, 2017, 26, 590-591.	0.3	4
303	Treatment of psoriatic arthritis with traditional DMARDs and novel therapies: approaches and recommendations. Expert Review of Clinical Immunology, 2017, 13, 319-331.	1.3	7
304	Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. Journal of Dermatological Treatment, 2017, 28, 374-383.	1.1	35
305	A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population. Clinical and Experimental Immunology, 2017, 187, 251-258.	1.1	21
306	Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. British Journal of Dermatology, 2017, 176, 650-658.	1.4	165
307	Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study. British Journal of Dermatology, 2017, 177, 297-298.	1.4	1
308	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology, 2017, 56, 2109-2113.	0.9	70
309	Unerwünschte Wirkungen von Biologika bei Psoriasis. Karger Kompass Dermatologie, 2017, 5, 195-199.	0.0	1
310	Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2065-2075.	2.0	25
311	The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE). Annals of Dermatology, 2017, 29, 462.	0.3	21
312	The Role of Methotrexate in Psoriatic Therapy in the Age of Biologic and Biosimilar Medication: Therapeutic Benefits versus Toxicology Emergencies. , 0, , .		2
313	Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database. Annals of Dermatology, 2017, 29, 761.	0.3	77
314	Curcumin nanoparticles potentiate therapeutic effectiveness of acitretin in moderate-to-severe psoriasis patients and control serum cholesterol levels. Journal of Pharmacy and Pharmacology, 2018, 70, 919-928.	1.2	50
315	Comparison of Lipid Accumulation Product Index with Body Mass Index and Waist Circumference as a Predictor of Metabolic Syndrome in Indian Population. Metabolic Syndrome and Related Disorders, 2018, 16, 240-245.	0.5	42

#	ARTICLE	IF	CITATIONS
316	The Association Between <sc>HLA</sc> Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 756-762.	2.9	14
317	Increased psoriasis frequency in patients with familial Mediterranean fever. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 57-61.	0.4	11
318	Diagnóstico diferencial de la tinea capitis en el lactante. <i>Piel</i> , 2018, 33, 115-121.	0.0	0
319	Pediatric psoriasis: Evolving perspectives. <i>Pediatric Dermatology</i> , 2018, 35, 170-181.	0.5	66
320	Health-related quality of life in adolescents with psoriasis: an interview-based study. <i>British Journal of Dermatology</i> , 2018, 178, 1404-1411.	1.4	22
321	Self-care for older people with psoriasis. <i>British Journal of Community Nursing</i> , 2018, 23, 214-217.	0.2	4
322	Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1726-1735.	0.3	57
323	Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 606-614.	1.3	21
324	Are patients comprehending? A critical assessment of online patient educational materials. <i>Journal of Dermatological Treatment</i> , 2018, 29, 295-299.	1.1	14
325	Identifying Psoriasis and Psoriatic Arthritis Patients in Retrospective Databases When Diagnosis Codes Are Not Available: A Validation Study Comparing Medication/Prescriber Visit-Based Algorithms with Diagnosis Codes. <i>Value in Health</i> , 2018, 21, 110-116.	0.1	8
326	Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018, 53, 1-14.	0.8	20
327	Addressing comorbidities in psoriatic disease. <i>Rheumatology International</i> , 2018, 38, 219-227.	1.5	13
328	Psoriasis and the risk of diabetes: A prospective population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 315-322.e1.	0.6	86
329	Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists. <i>Dermatologic Therapy</i> , 2018, 31, e12567.	0.8	12
330	Managing psoriasis – how to answer questions patients ask?. <i>Independent Nurse</i> , 2018, 2018, 20-23.	0.0	0
331	Investigation of Psoriasis Susceptibility Loci in Psoriatic Arthritis and a Generalized Pustular Psoriasis Cohort. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S83-S85.	0.8	3
332	The association between psoriasis and health-related quality of life, work productivity, and healthcare resource use in Brazil. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 197-204.	0.5	16
333	Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2178-2184.	1.3	8

#	ARTICLE	IF	CITATIONS
334	Psoriasis in Taiwan: From epidemiology to new treatments. <i>Dermatologica Sinica</i> , 2018, 36, 115-123.	0.2	35
335	Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis. <i>Experimental Dermatology</i> , 2018, 27, 1053-1057.	1.4	7
336	Nail Unit Psoriasis. , 2018, , 99-126.		0
337	Psoriasis vulgarisâ€™ Pathophysiology of the disease and its classical treatment versus new drug delivery systems. , 2018, , 379-406.		7
338	Psoriasis in Israel: demographic, epidemiology, and healthcare services utilization. <i>International Journal of Dermatology</i> , 2018, 57, 1068-1074.	0.5	14
339	ERAP1 and HLA-C*06 are strongly associated with the risk of psoriasis in the population of northern Poland. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 286-292.	0.4	7
340	The epidemiology of psoriatic arthritis in Israel â€“ a population-based study. <i>Arthritis Research and Therapy</i> , 2018, 20, 3.	1.6	38
341	Gender Differences in Psoriasis. , 2018, , 63-81.		2
342	A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 350-358.	2.3	11
343	Dietary compounds as potential modulators of microRNA expression in psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986480.	1.1	63
344	ALAâ€™ PDT alleviates the psoriasis by inhibiting JAK signalling pathway. <i>Experimental Dermatology</i> , 2019, 28, 1227-1236.	1.4	14
345	Epidemiology and Comorbidities of Psoriasis among Israeli Adolescents: A Large Cross-Sectional Study. <i>Dermatology</i> , 2019, 235, 488-494.	0.9	11
346	Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study. <i>Journal of Dermatology</i> , 2019, 46, 752-758.	0.6	12
348	Efficacy and safety of 308â€™m excimer lamp in the treatment of scalp psoriasis: a retrospective study. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 172-177.	0.7	6
349	Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide populationâ€™based cohort study in Taiwan. <i>Journal of Dermatology</i> , 2019, 46, 604-609.	0.6	18
350	Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1630-1639.	0.6	5
351	A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. <i>Pediatric Dermatology</i> , 2019, 36, 290-297.	0.5	30
352	Epidemiology of Psoriasis. A Population-Based Study. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2019, 110, 385-392.	0.2	7

#	ARTICLE	IF	CITATIONS
354	The illness-death model for family studies. <i>Biostatistics</i> , 2021, 22, 482-503.	0.9	1
355	Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. <i>Annales De Dermatologie Et De Venereologie</i> , 2019, 146, 363-371.	0.5	16
356	Benefitâ€‘risk profile of tofacitinib in patients with moderateâ€‘toâ€‘severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.4	33
357	Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study. <i>Journal of Clinical Psychology in Medical Settings</i> , 2019, 26, 200-219.	0.8	16
358	Características epidemiológicas de la psoriasis. Un estudio poblacional. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 385-392.	0.2	12
359	The Prevalence of Comorbidities in Children and Young Adults With Psoriasis and Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 22-27.	0.3	2
360	Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. <i>Journal of Dermatological Treatment</i> , 2019, 30, 545-548.	1.1	6
361	Evaluation of Galectin3 levels in psoriatic patients treated by narrow-band UVB phototherapy. <i>Journal of Dermatological Treatment</i> , 2020, 31, 758-762.	1.1	2
362	Testing the heritability and parentâ€‘ofâ€‘origin hypotheses for ages at onset of psoriatic arthritis under biased sampling. <i>Biometrics</i> , 2020, 76, 293-303.	0.8	3
363	The impact of chronic skin disease in adolescence and the need for specialist adolescent services. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 5-9.	0.6	19
364	Joint American Academy of Dermatologyâ€‘National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	0.6	129
365	A systematic review of cognitive and behavioral treatments for individuals with psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 631-638.	1.1	10
366	Safety and efficacy of topical, fixedâ€‘dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1098-1104.	1.3	3
367	Quality of life outcomes in adults with moderateâ€‘toâ€‘severe plaque psoriasis treated with dimethylfumarate (<sc>DMF</sc>): a post hoc analysis of the <sc>BRIDGE</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 119-126.	1.3	15
368	Nonbullous Skin Diseases: Alopecia Areata, Vitiligo, Psoriasis, and Urticaria. , 2020, , 1211-1234.		2
369	Psoriasis, cardiovascular risk factors and metabolic disorders: sexâ€‘specific findings of a populationâ€‘based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 779-786.	1.3	26
370	Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 85-93.	1.6	11
371	Épidémiologie du rhumatisme psoriasique. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 245-248.	0.0	2

#	ARTICLE	IF	CITATIONS
372	<p><p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>. Psoriasis: Targets and Therapy, 2020, Volume 10, 23-28.	1.2	1
373	<p>Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives</p>. Psoriasis: Targets and Therapy, 2020, Volume 10, 45-56.	1.2	3
374	Pregnancy Outcome in Inflammatory Arthropathies â€” Are Population Database Studies the Right Tool?. Journal of Rheumatology, 2020, 47, 161-163.	1.0	3
375	Benefits of turmeric supplementation for skin health in chronic diseases: a systematic review. Critical Reviews in Food Science and Nutrition, 2021, 61, 3421-3435.	5.4	7
377	Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis. The Cochrane Library, 2020, 5, CD011941.	1.5	4
378	Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 715-721.	0.7	6
379	Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (â‰¥ 6 to <lt; Tj ETQq0 0 0 rgBT /Ove<sc>CADMUS</sc> Jr study. British Journal of Dermatology, 2020, 183, 664-672.	1.4	53
380	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. BMC Neurology, 2020, 20, 106.	0.8	4
381	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. Journal of the American Academy of Dermatology, 2020, 82, 1337-1345.	0.6	9
382	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, 2022, 33, 740-748.	1.1	5
383	A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (United States), 2020, 99, e19303.	0.4	26
384	Chronic inflammatory diseases, myocardial function and cardioprotection. British Journal of Pharmacology, 2020, 177, 5357-5374.	2.7	24
385	Reviewâ€”Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis. International Journal of Molecular Sciences, 2020, 21, 699.	1.8	45
386	Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms and psoriasis susceptibility: A systematic review and meta-analysis. Gene, 2020, 736, 144416.	1.0	2
387	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatology and Therapy, 2020, 10, 351-364.	1.4	18
388	Efficacy and safety of ixekizumab in a phase <sc>III</sc> , randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis () Tj ETQq1 1 0.784314 rgBT /Ove	1.4	14
389	Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*. British Journal of Dermatology, 2021, 184, 243-258.	1.4	65
390	Association between psoriasis, psoriatic arthritis and gastrointestinal disease. Wiener Klinische Wochenschrift, 2021, 133, 586-593.	1.0	9

#	ARTICLE	IF	CITATIONS
391	How do we treat psoriasis patients with hepatitis C infections in real-world situations? A retrospective analysis of 34 patients. <i>Journal of Dermatological Treatment</i> , 2021, 32, 321-327.	1.1	4
392	Dual inhibition of IL-17A and IL-17F in psoriatic disease. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110378.	1.1	26
393	Gender and age characteristics of the psoriasis prevalence among the population of the Tambov region: data analysis from the electronic medical records. <i>Klinicheskaya Dermatologiya i Venerologiya</i> , 2021, 20, 26.	0.0	0
394	Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. <i>Dermatologic Therapy</i> , 2021, 34, e14849.	0.8	9
395	Clinico-Epidemiological Characteristics and Impact on Quality of Life in Psoriatic Patients with and without Nail Changes - A Nepalese Experience. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 306-312.	0.0	0
396	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 144-149.	1.6	10
397	Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort. <i>Pediatric Rheumatology</i> , 2021, 19, 45.	0.9	13
398	Evaluation of treatment satisfaction misalignment between Japanese psoriasis patients and their physicians – Japanese psoriasis patients and their physicians do not share the same treatment satisfaction levels. <i>Current Medical Research and Opinion</i> , 2021, 37, 1103-1109.	0.9	3
399	Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease. <i>Current Problems in Cardiology</i> , 2021, 46, 100799.	1.1	11
400	Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: North American Contact Dermatitis Group data, 2001–2016. <i>Contact Dermatitis</i> , 2021, 85, 435-445.	0.8	3
401	Psoriatic arthritis. <i>Journal of Dermatology</i> , 2021, 48, 741-749.	0.6	13
402	Moderate to severe psoriasis: a single-center analysis of gender prevalence. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	4
403	New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab. <i>Meditinskiy Sovet</i> , 2021, , 40-50.	0.1	0
404	Psoriatic arthritis in Africa. <i>Clinical Rheumatology</i> , 2021, 40, 3411-3418.	1.0	1
405	Adverse impact of occupational exposure on Laborers of cement industry have scalp psoriasis and Pityriasis amiantacea with deficiency of zinc and selenium: impact of mineral supplement. <i>Environmental Science and Pollution Research</i> , 2021, , 1.	2.7	1
406	Paradoxical psoriasis in pediatric patients: A systematic review. <i>Pediatric Dermatology</i> , 2021, 38, 1086-1093.	0.5	9
407	Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 343, 114-121.	0.8	4
408	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757.	0.6	20

#	ARTICLE	IF	CITATIONS
409	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	1.4	34
410	“Not just a piece of skin in front of you” a qualitative exploration of the experiences of adolescents with eczema and psoriasis with healthcare professionals. <i>BMJ Open</i> , 2021, 11, e041108.	0.8	7
414	Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 379-386.	1.0	14
415	Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. <i>Singapore Medical Journal</i> , 2020, 61, 194-199.	0.3	9
416	High Prevalence of Skin Diseases and Need for Treatment in a Middle-Aged Population. A Northern Finland Birth Cohort 1966 Study. <i>PLoS ONE</i> , 2014, 9, e99533.	1.1	26
417	Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan. <i>PLoS ONE</i> , 2016, 11, e0149316.	1.1	16
418	Hyperhidrosis Prevalence and Demographical Characteristics in Dermatology Outpatients in Shanghai and Vancouver. <i>PLoS ONE</i> , 2016, 11, e0153719.	1.1	40
419	Evaluation of Psoriasis Genetic Risk Based on Five Susceptibility Markers in a Population from Northern Poland. <i>PLoS ONE</i> , 2016, 11, e0163185.	1.1	15
420	Biologics and small molecules in psoriasis: A systematic review of economic evaluations. <i>PLoS ONE</i> , 2018, 13, e0189765.	1.1	14
421	Assessment of the effect of psoriasis on male sexual function. <i>Human Andrology</i> , 2019, 8, 69-75.	0.2	1
422	Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. <i>Health Technology Assessment</i> , 2015, 19, 1-176.	1.3	31
423	Management of Pediatric Psoriasis. <i>Pediatric Annals</i> , 2012, 41, e1-7.	0.3	27
424	The pattern of psoriatic arthritis in Kashmir: A 6-year prospective study. <i>North American Journal of Medical Sciences</i> , 2015, 7, 356.	1.7	2
425	Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk. <i>World Journal of Cardiology</i> , 2016, 8, 667.	0.5	12
426	The Prevalence of Psoriasis and Vitiligo in a Rural Area in Turkey. <i>Journal of the Turkish Academy of Dermatology</i> , 2012, 6, .	0.1	4
427	Relationship between Tumor Necrosis Factor- α Inhibitors and Cardiovascular Disease in Psoriasis: A Review. , 2014, 18, 49-54.		15
428	Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control Study. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, WC01-5.	0.8	27
429	Role of Unani (Greek) Therapy in the Treatment of Psoriasis Case Series. <i>IOSR Journal of Dental and Medical Sciences</i> , 2016, 15, 24-27.	0.0	1

#	ARTICLE	IF	CITATIONS
430	Clinical implications of intermittent Ramadan fasting on stable plaque psoriasis: a prospective observational study. <i>Postepy Dermatologii I Alergologii</i> , 2022, 39, 368-374.	0.4	7
431	Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis. <i>Clinical Drug Investigation</i> , 2021, 41, 1011-1020.	1.1	10
432	Management of psoriasis in children (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1429.	0.8	7
433	Haut und Gelenke â€” Sicht des Rheumatologen. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2009, , 396-402.	0.0	1
435	The Role of Cardiovascular Disease in the Patient with Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 42-55.	0.1	0
436	Glutathione S-transferase M1 (GSTM1) genotype but not GSTT1 or MC1R genotype influences erythematous sensitivity to narrow band (TL-01) UVB phototherapy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 217-224.	0.7	11
437	Renal Infarction in a Patient with Psoriasis: Case Report. <i>Turkiye Klinikleri Journal of Medical Sciences</i> , 2013, 33, 259-262.	0.1	0
438	Nanotechnology Applications in Dermatology. , 2013, , 85-194.		0
439	Topical and Transdermal. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 219-238.	0.2	0
440	Current evidence on the effectiveness of systemic herbal medicine for psoriasis: A systematic review with meta-analysis. <i>Global Dermatology</i> , 2015, 2, .	0.1	1
441	Efficacy of topical Calcipotriol versus combination of topical Calcipotriol plus Betamethasone in the treatment of plaque type psoriasis. <i>Journal of Armed Forces Medical College Bangladesh</i> , 2015, 10, 74-79.	0.1	0
442	Prevalence of metabolic syndrome in Psoriasis â€” a case control study. <i>International Journal of Medical Research and Review</i> , 2015, 3, 404-408.	0.1	0
443	ONICOMICOSE E PSORÃASE UNGUEAL. <i>Journal of the Portuguese Society of Dermatology and Venereology</i> , 2015, 73, 211-218.	0.0	0
444	Comparative Efficacy of Topical Calcipotriol (0.005%) Versus Topical Corticosteroid (Betamethasone) Tj ETQq1 1 0,784314 rgBT /Oved	0.0	0
445	STUDY OF EFFECT OF METHOTREXATE ON PSORIASIS IN COMPARISON WITH AZATHIOPRINE. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2015, 2, 6916-6919.	0.0	0
446	THE RELATION BETWEEN ENVIRONMENTAL STRESSORS AND SEVERITY OF THE CLINICAL PROFILE OF PSORIASIS IN AN EGYPTIAN SAMPLE. <i>Journal of Environmental Science</i> , 2016, 33, 121-143.	0.0	0
449	The Risk and Associated Factors of Female Sexual Dysfunction (FSD) in Women with Psoriasis. <i>IJUM Medical Journal Malaysia</i> , 2017, 16, .	0.1	1
450	Psoriasis in Jordan : A Single Center Experience. <i>Journal of the Royal Medical Services</i> , 2017, 24, 6-10.	0.0	0

#	ARTICLE	IF	CITATIONS
451	Epidemiological aspects of psoriasis in children. <i>Klinicheskaya Dermatologiya I Venerologiya</i> , 2018, 17, 24.	0.0	3
452	Association of HLA-C*06 with Psoriasis in a Tertiary Care Hospital. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2020, 9, 1563-1566.	0.1	0
453	HLA- A & B Association in Psoriasis in Tamil Speaking South Indian Population. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2020, 9, 1782-1786.	0.1	0
454	Psoriasis in Pediatrics. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 496-499.	0.1	1
455	Biological Therapy Survivability in Children with Psoriasis: Cohort Study. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2021, 20, 451-458.	0.1	5
456	Pediatric Psoriasis. , 2021, , 311-342.		0
457	Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 582-8.	0.4	22
458	Biologic safety in psoriasis: review of long-term safety data. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 30-42.	0.1	11
459	Treatment Satisfaction Among Patients with Moderate-to-severe Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 26-30.	0.1	16
460	Feasibility of carotid artery PET/MRI in psoriasis patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 223-33.	1.0	3
461	Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 2010-2020.e8.	1.5	37
462	Quality of life assessment among children with psoriasis. <i>Medicina I FiziÄeskaÅ¢ KulÊtura: Nauka I Praktika</i> , 2021, , 41-48.	0.1	1
463	Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 16-23.	0.2	6
464	Immune mechanisms of psoriasis. New strategies of biotherapy. <i>Vestnik Dermatologii I Venerologii</i> , 2010, 86, 35-47.	0.2	11
465	Prevalence of Atopic Dermatitis in Italian Schoolchildren: Factors Affecting its Variation. <i>Acta Dermato-Venereologica</i> , 2008, 89, 122-125.	0.6	26
467	Age- and Sex-Adjusted Prevalence Estimates Among Pediatric Patients with Psoriasis in the United States. <i>British Journal of Dermatology</i> , 2022, , .	1.4	0
468	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-240.	0.4	0
469	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.4	32

#	ARTICLE	IF	CITATIONS
470	An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5834.	1.0	11
471	Effective topical treatments using innovative NNO-tridentate vanadium(<i>iv</i>) complexes-mediated photodynamic therapy in a psoriasis-like mouse model. <i>Journal of Materials Chemistry B</i> , 2022, 10, 4759-4770.	2.9	8
472	Low prevalence of patients diagnosed with psoriasis in Nuuk: a call for increased awareness of chronic skin disease in Greenland. <i>International Journal of Circumpolar Health</i> , 2022, 81, 2068111.	0.5	2
473	Comparative Effectiveness and Safety of Methotrexate Versus PUVA in Severe Chronic Stable Plaque Psoriasis. <i>Indian Journal of Dermatology</i> , 2021, 66, 371-377.	0.1	2
474	Curcumin: A Review of its™ Efficacy in the Management of Psoriasis. <i>Drug Delivery Letters</i> , 2022, 12, 163-183.	0.2	2
475	Association between psoriasis and alopecia areata: A systematic review and meta-analysis. <i>Journal of Dermatology</i> , 2022, 49, 912-915.	0.6	6
476	Performance of Coronary Artery Calcium Testing in Patients With Severe Psoriasis: Risk Assessment and Reclassification Potential in a Low Cardiovascular Risk Population. <i>Actas Dermo-sifiligráficas</i> , 2022, 113, 773-780.	0.2	2
477	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venerologica</i> , 2022, 102, adv00733.	0.6	2
478	Current clinical features in the course of psoriasis and psoriasiform states in children. <i>Vestnik Dermatologii I Venerologii</i> , 2011, 87, 38-43.	0.2	1
479	Psoriasis incidence and prevalence in the Russian Federation. <i>Vestnik Dermatologii I Venerologii</i> , 2012, 88, 20-29.	0.2	11
480	Results of a study of genetic factors predisposing to the development of psoriasis among the population of the Russian Federation. <i>Vestnik Dermatologii I Venerologii</i> , 2013, 89, 78-90.	0.2	0
481	Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children. <i>Medical Alphabet</i> , 2022, , 80-85.	0.0	2
482	The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. <i>International Journal of Women's Dermatology</i> , 2022, 8, e010.	1.1	19
484	Update on the Management of Pediatric Psoriasis: An Italian Consensus. <i>Dermatology and Therapy</i> , 2022, 12, 1753-1775.	1.4	11
485	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation. <i>Dermatology and Therapy</i> , 2022, 12, 2063-2075.	1.4	2
486	Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 439-453.	2.7	16
487	Vitamin D status in Psoriasis: impact and clinical correlations. <i>BMC Nutrition</i> , 2022, 8, .	0.6	5
489	Psychological Characteristics of Children with Psoriasis. <i>Open Dermatology Journal</i> , 2022, 16, .	0.5	0

#	ARTICLE	IF	CITATIONS
490	HLA-C Genotyping Reveals Haplotype C*07 as a Potential Biomarker of Late Psoriasis Onset in Moroccan Patients. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1012-1023.	1.0	0
491	Additive prognostic value of longitudinal myocardial deformation to SCORE2 in psoriasis. <i>European Heart Journal Open</i> , 2023, 3, .	0.9	0
492	Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion. <i>JAMA Dermatology</i> , 2023, 159, 289.	2.0	4
493	MRI Findings in Axial Psoriatic Spondylarthritis. <i>Diagnostics</i> , 2023, 13, 1342.	1.3	3